The anastrozole, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial in post-menopausal women: Regional variations in surgical practice in patients recruited into the trial. The ATAC Trialists' Group.

被引：0

作者：

Sainsbury, R ^{[1
]}

机构：

[1] Huddersfield Royal Infirm, Huddersfield, W Yorkshire, England

来源：

ANNALS OF ONCOLOGY | 2000年 / 11卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

78P

引用

页码：20 / 20

页数：1

共 38 条

[31] Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC): a UK National Health Service (NHS) perspective. The ATAC Trialists' Group
Mansel, Robert E.
ANNALS OF ONCOLOGY, 2004, 15 : 65 - 65
[32] Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
Gershon Y. Locker
Robert Mansel
David Cella
Deborah Dobrez
Sonja Sorensen
Sanjay K. Gandhi
Breast Cancer Research and Treatment, 2007, 106 : 229 - 238
[33] Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
Locker, Gershon Y.
Mansel, Robert
Cella, David
Dobrez, Deborah
Sorensen, Sonja
Gandhi, Sanjay K.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (02) : 229 - 238
[34] The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months
Aman Buzdar
Breast Cancer Research and Treatment, 2003, 77 (3) : 295 - 295
[35] The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 5 years
Howell, A
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S7 - S7
[36] Polychemotherapy (CT) in pre- and post-menopausal women with early breast cancer prescribed 5 years tamoxifen (T) - results from the UKNCRI Adjuvant Breast Cancer (ABC) international trial in 1991 patients.
Barrett-Lee, PJ
Bliss, JM
Brunt, AM
Dehshiri, K
Harnett, AN
Johnson, L
Lawrence, D
Robinson, A
Weerasekera, K
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 41S - 41S
[37] Long term follow-up of the neo-adjuvant pilot trial evaluating activity of letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive primary breast cancer
Forero, A.
Delos Santos, J.
Bowen, K.
Jones, C.
Varley, K. E.
Nabell, L.
Carpenter, J. T.
Falkson, C. I.
Krontiras, H.
Caterinicchia, V.
O'Malley, J.
Li, Y.
LoBuglio, A. F.
Myers, R.
Saleh, M. N.
CANCER RESEARCH, 2013, 73
[38] Two years of tamoxifen followed by 3 years of anastrozole versus 5 years of tamoxifen alone in postmenopausal women with hormone-responsive early breast cancer: Efficacy results from 3,714 patients from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 8.
Dubsky, P. C.
Jakesz, R.
Greil, R.
Heck, D.
Stoeger, H.
Kwasny, W.
Menzel, C.
Singer, C. F.
Medl, M.
Gnant, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 →